ERBB2 and breast cancer: However, the recently reported INFORM study, in which BRCA1/2-germline mutation carriers with HER2-negative early BC were randomized to receive cisplatin 75 mg/m2 vs. classical AC, both for 4 cycles before surgery, failed to demonstrate any advantage in terms of pCR for cisplatin in this population [57].